NCT05283915View on ClinicalTrials.gov

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 18, 2022

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Hepatic Function Abnormal
Interventions
DRUG

tolebrutinib

Pharmaceutical form: Film-coated tablet Route of administration: oral

Trial Locations (2)

33014

Clinical Pharmacology of Miami Site Number : 8400002, Miami

55114

Nucleus Network Site Number : 8400001, Saint Paul

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05283915 - Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic Function | Biotech Hunter | Biotech Hunter